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Abstract
Objectives: Refugees and immigrants from developing countries settling in industrialised countries have a high prevalence
of Helicobacter pylori (H. pylori). Screening these groups for H. pylori and use of eradication therapy to reduce the future
burden of gastric cancer and peptic ulcer disease is not currently recommended in most countries. We investigated whether
a screening and eradication approach would be cost effective in high prevalence populations.
Methods: Nine different screening and follow-up strategies for asymptomatic immigrants from high H. pylori prevalence
areas were compared with the current approach of no screening. Cost effectiveness comparisons assumed population
prevalence’s of H. pylori of 25%, 50% or 75%. The main outcome measure was the net cost for each cancer prevented for
each strategy. Total costs of each strategy and net costs including savings from reductions in ulcers and gastric cancer were
also calculated.
Results: Stool antigen testing with repeat testing after treatment was the most cost effective approach relative to others, for
each prevalence value. The net cost per cancer prevented with this strategy was US 111,800 (assuming 75% prevalence),
132,300 (50%) and 193,900 (25%). A test and treat strategy using stool antigen remained relatively cost effective, even
when the prevalence was 25%.
Conclusions: H. pylori screening and eradication can be an effective strategy for reducing rates of gastric cancer and peptic
ulcers in high prevalence populations and our data suggest that use of stool antigen testing is the most cost effective
approach.
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Introduction
Estimates suggest that half of the world’s population is infected
with H. pylori. Sero-prevalence studies in lower and middle
income countries show rates of exposure above 80% [1]. H. pylori
infection is usually acquired in childhood [1]. Colonisation persists
for decades and is potentially lifelong, leading to chronic
gastrointestinal inflammation, and stomach and duodenal ulcers.
H. pylori is also a major causative agent in the development of
gastric cancer [1], and cancer occurs in 0.1–3% of those
chronically infected [1]. Gastric cancer is the second most
common cause of cancer death worldwide leading to 736,000
deaths annually [2], including 11000 in the United States [3]. The
mean 5 year net cost of a patient with gastric cancer is over 50000
[4], and the five year survival rate is less than 20% [5]. Eradication
of H. pylori has been shown to reduce progression to precancerous
changes in the stomach [6], and to reduce the risk of developing
gastric cancer by approximately one third [7].
Refugees and immigrants settling in western countries often
have high rates of H. pylori infection (72–93%) [8,9], as compared
to the local population [8]. In Canada, overseas birth and
immigration after 20 years of age were both shown to be risk
factors for H. pylori infection [10]. Mexico, the largest source
country for US immigration, has an H. pylori prevalence of 60%
in serological surveys of 20 year olds [11]. More than 80% of
African refugee children in Australia have positive stool antigen
tests on arrival [9].
Approximately 12.5% (38.5 million) of the US population were
born overseas, of whom 85% come from low or middle income
countries [12]. Currently, neither H. pylori nor gastric cancer
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screening are recommended for this group if asymptomatic, with
most guidelines recommending testing based on symptoms.
However, it is recognised that detection based on symptoms can
miss a significant burden of H. pylori infection [8] and gastric
cancer [13].
A number of testing modalities exist for the detection of H.
pylori. Serology is widely available and has a sensitivity of 92%
(25% IQR 85–96%) and specificity of 83% (25% IQR 73–92%)
depending on the test kit used [14]. Antibody levels decline slowly
after eradication of H. pylori infection so a positive serology result
may reflect past rather than current infection. Stool antigen testing
is relatively inexpensive, monoclonal enzyme immunoassay (EIA)
testing has a sensitivity of 94% (95% CI 93–95%) and specificity of
97% (95% CI 96–98%) [15]. Breath testing is a rapid, non-
invasive test with a high sensitivity (95%) and specificity (98%) but
is more expensive [16]. Gastroscopy with biopsy and culture
remains the gold standard for H. pylori detection but is costly and
more logistically challenging.
In this study we hypothesized that screening for and eradication
of H. pylori in high prevalence populations would be cost-effective.
Our objectives were to model the effect of various H. pylori
screening strategies on the incidence of gastric cancer and ulcer
disease in populations with different prevalence’s of infection, and
to compare the relative cost-effectiveness of each strategy
(including savings accrued through prevention of gastric cancer
and reduced burden of ulcer disease).
Methods
Costs of test and treat strategies were compared to no screening
and to empiric treatment strategies, both of which require no
testing. Nine different screening and follow-up strategies were
investigated (Figure 1).The empiric treatment approach was
included as a comparator and may have a role in very high
prevalence populations.
Costs were calculated as total costs for each strategy and benefit
as the total cost of the outcome prevented. Primary benefits were
the prevention of gastric cancer and the prevention of peptic ulcer
disease, compared to no screening or treatment. Net costs were
total costs minus savings accrued due to benefits of screening
(ulcers and gastric cancers prevented).
The likelihood of a particular testing outcome was based on
sensitivity and specificity values for the tests used (Table 1). Models
were developed using decision analysis trees with the endpoints
being total and net cost of the strategy and number of gastric
cancers and ulcers prevented. Costs and treatment efficacy were
based on published estimates (Table 1 & 2).
Each model included the cost of the physician visits, which were
assumed to be only for H. pylori management and not as part of
other care or screening. It was assumed tests or empiric treatment
(with a proton pump inhibitor (PPI), clarithromycin and amox-
icillin), would be ordered during this initial visit. Strategies with a
single time-point for testing were assumed to require up to two
physician visits, with the second visit being needed only for those
who required treatment because of positive testing. Strategies
involving retesting were assumed to require up to three physician
visits. Non-medical and indirect costs were not included, in
keeping with other comparable modelling papers [5]. While a
small proportion of individuals remain H. pylori positive after two
courses of treatment, (the second course of treatment with PPI,
bismuth, tetracycline and metronidazole) and require subsequent
further testing and treatment, this scenario was not included. It is
recognized that certain strains of H. pylori have higher risk of
progression to gastric cancer [17]. As immigrants arrive from a
multitude of countries from which strain prevalence varies or is not
known, a standard risk of progression to cancer was used.
Costs were calculated in US dollars for 2011. Costs from earlier
years were adjusted for inflation to bring them to 2011 values
(Table 2). Analyses were performed for each strategy at three
prevalence values (25%, 50% and 75%) with net costs per cancer
prevented calculated for each strategy (Table 3). Total costs and
numbers of cancers and ulcers prevented with each strategy
(expressed per 1000 patients managed) were also calculated
(Table 4).
Sensitivity analysis was performed on the most cost-effective
strategy in the initial analysis (stool testing with retesting of those
treated). The outcome measure of interest was the net cost per
Figure 1. H. pylori management strategies included in the analysis.
doi:10.1371/journal.pone.0108610.g001
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cancer saved. The parameters tested were cost of managing one
cancer, cost of a physician visit, cost of medication for eradication,
cost of managing one peptic ulcer and lifetime risk of gastric
cancer. The change in net cost per cancer saved was estimated
against the proportional change in each of the five parameters. A
probabilistic model was developed in which the model parameters
were drawn from their full uncertainty distributions, as given in
Table 1. The distributions were assumed to be normal with the
mean equal to the best estimate and upper and lower range equal
to the 95% area under the curve of the normal distribution. For
each of 10,000 iterations, a parameter was drawn from each
uncertainty distribution and results calculated; including costs,
number of cancers averted, number of ulcers averted false
negatives and positive results. Sensitivity to change in parameters
was estimated using multivariable regression, with cost per cancer
saved as the continuous outcome variable and the parameters
above as the predictor variables. Linear relationships were
assumed and the parameters were not transformed. Figures
represent the effect on cost per cancer prevented if each parameter
was increased by 1% of the original estimate used.
Results
For all three prevalence rates tested, the most cost effective
approach relative to others was testing with stool antigen, with
treatment for those who tested positive followed by retesting and
further treatment if the initial treatment failed (Figure 2, 3, 4).
When the prevalence was assumed to be 75%, the estimated net
cost per cancer prevented was 111800 (strategy 3bi) (Table 3).
For every 1000 people managed under this strategy we expect that
Table 1. Testing and treatment parameters used including estimated ranges around each parameter.
Parameter Best estimate Lower range Upper range Distribution Reference
Testing for H.pylori
Breath test
Sensitivity (%) 95.3 92.2 97.5 95%CIa [16]
Specificity (%) 97.7 94.8 99.3 95%CI [16]
Serology
Sensitivity (%) 92 85 96 IQRb [14]
Specificity (%) 83 73 92 IQR [14]
Stool Antigen
Sensitivity (%) 94 93 95 95%CI [15]
Specificity (%) 97 96 98 95%CI [15]
Gastroscopy with biopsy
Sensitivity (%) 95 90 99 [36]
Specificity (%) 99 95 100 [36]
Treatment of H. pylori
HP7 efficacy 77% 27% 97% full range [29,37]
2nd line treatment efficacy 90% 85% 95% [38]
Sequential therapy efficacy 93% 91% 95% 95%CI [37]
Benefits of H.pylori eradication
Reduction in gastric cancers RRc 0.56 RR 0.4 RR 0.8 95%CI [7]
Reduction in duodenal ulcers RR 0.37 RR 0.26 RR 0.53 95% CI [22]
Other
Incidence of Peptic Ulcer disease 0.19% 0.10% 0.19% [39]
Prevalence of Peptic Ulcer disease 1.50% 0.12% 1.50% [39]
Incidence of duodenal ulcer if H. pylori +ve 5% 0.18% 17% 95% CI [21]
Treatment adverse effects (all)
Comparison 8% [22]
Treatment 22% [22]
Cancer Survival (%)
1 year 41 39 42 95%CI [5]
2 year 26 25 28 95%CI [5]
3 year 21 19 22 95%CI [5]
4 year 18 16 19 95%CI [5]
5 year 16 14 17 95%CI [5]
aCI = 95% Confidence Interval.
bIQR = Interquartile range.
cRR = Relative Risk.
doi:10.1371/journal.pone.0108610.t001
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3.0 gastric cancers and 22.8 ulcers would be prevented (Table 4).
At 50% prevalence the net cost per cancer prevented was
estimated to be 132300, with prevention of 2.0 cancers and 15.2
ulcers per 1000 people managed. At 25% prevalence the net cost
per cancer prevented was estimated to be 193900, with
prevention of 1.0 cancer and 7.6 ulcers per thousand people
managed (Tables 3 & 4).
Treating all individuals without screening was also a relatively
cost effective strategy in a high prevalence (75%) population, with
a net cost per cancer prevented of 116600 (Table 3), although the
overall number of cancers (2.5/1000 treated) and ulcers (18.2/
1000 treated) prevented was lower than with a strategy involving
retesting and further treatment (Table 4). At a lower prevalence
estimate of 25% (Table 4) the cost of treatment became a very
significant burden with the treat-all strategy because most of the
population would receive unnecessary treatment. At 25% preva-
lence the strategy with the lowest cost of testing (stool antigen
testing) offered the lowest overall cost, and post treatment testing
and retreatment improved the net benefit.
The use of serology was more expensive at all prevalence levels
tested and breath test, although having slightly better sensitivity
and specificity than stool antigen, was considerably more
expensive. Any strategy that involved the use of gastroscopy had
considerably higher net costs per cancer prevented (Table 3) and
total costs (Table 4). The net costs were slightly lower than the
total costs indicating that the cost savings from preventing gastric
cancer and ulcer disease contributed only a small component of
the cost/benefit of each strategy.
Table 2. Costs of testing and treatment for H.pylori, and costs of adverse outcomes associated with H.pylori in US dollars.
Costs (in US$) Original figure (US$) Converted to 2011 (US$) Reference
Testing and Treatment
Physician visit 86 86 [40]
Serology 29 30 [41]
Breath test 133 140 [41]
Stool antigen 21 22 [41]
Eradication therapy 355 373 [41]
Gastroscopy with biopsy 550 636 [21]
Peptic ulcer annual cost
Peptic Ulcer Costs 866 1582 [42]
Gastric Cancer costs
Mean cost of gastric cancer care (5 year net in 2004)
Men 44203 52712 [4]
Women 41899 49965 [4]
doi:10.1371/journal.pone.0108610.t002
Table 3. Net cost per cancer prevented (US dollars) for each strategy at varying prevalence rates of H. pylori.
Net cost per cancer prevented Prevalence
Management Options 25% 50% 75%
1) No screening 0 0 0
2) Treat all 477800 206900 116600
3) Screen and Treatment
a. Serology
No follow up 294700 169900 128300
b. Stool Ag
No follow up 219200 142700 117100
i) Follow with stool Ag and retreat 193900 132300 111800
c. Breath test
No follow up 360200 213800 165000
i) Follow with breath test and retreat 334600 216400 177000
d. Gastroscopy
No follow up 972000 520600 370200
i) Follow up gastroscopy and retreat 939900 577200 456300
ii) Follow with breath test and retreat 820200 460100 340100
iii) Follow with stool Ag and retreat 794400 433900 313700
doi:10.1371/journal.pone.0108610.t003
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Figure 2. Net cost per number of cancers prevented for different strategies for screening and treatment of H. pylori in a population
with a 75% prevalence of H. pylori infection shown as an Incremental Cost Effectiveness Ratio (ICER). Red line indicates lowest net cost
per cancer prevented.
doi:10.1371/journal.pone.0108610.g002
Figure 3. Net cost per number of cancers prevented for different strategies for management of H. pylori in a population with a 50%
prevalence of H. pylori infection (ICER). Red line indicates lowest net cost per cancer prevented.
doi:10.1371/journal.pone.0108610.g003
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Figure 4. Net cost per number of cancers prevented for different strategies for screening and treatment of H. pylori in a population
with a 25% prevalence of H. pylori infection (ICER). Red line indicates lowest net cost per cancer prevented.
doi:10.1371/journal.pone.0108610.g004
Figure 5. Sensitivity analysis for the most cost effective strategy (stool antigen with retesting). Horizontal bars represent the estimated
net effect on cost per cancer prevented in US Dollars with a 1% increase in the listed parameters.
doi:10.1371/journal.pone.0108610.g005
Helicobacter pylori in Immigrants and Refugees
PLOS ONE | www.plosone.org 7 September 2014 | Volume 9 | Issue 9 | e108610
Figure 5 shows the sensitivity analysis for each of three
prevalence values, using strategy 3bi, the optimal strategy.
Parameters that represent the consequences of untreated H.pylori
(peptic ulcer and gastric cancer) have negative values because as
these costs rise, the value of eradicating H.pylori increases, the
cost-effectiveness increases, and the net cost per cancer averted
decreases. The parameters associated with the cost of the strategy
have positive values, since as costs rise for any intervention, the
cost per cancer averted rises. The cost of eradication therapy was
the greatest cost associated with the strategy at high prevalence,
while the risk of gastric cancer contributed significantly to the
benefit of the strategy. Any increase in the estimated lifetime
incidence of gastric cancer results in a significant decrease in the
net cost per cancer prevented.
Discussion
Screening and treatment of H. pylori in high-risk populations
has been suggested as a means of reducing the burden of gastric
cancer and peptic ulceration [8,18] and been shown to be cost
effective [19] however this is not routinely undertaken in Western
countries [18]. Immigrants from developing countries represent a
group with a high prevalence of H. pylori and hence a target group
for screening strategies. Our modelling has shown that the costs
associated with most of the available ‘test and treat’ strategies are
not prohibitive. In particular, the use of a cheap and easily
available stool antigen test has the potential to significantly lower
the overall costs of screening, and deserves consideration in
populations with high prevalence’s of H. pylori. Notably the
number of cancers and ulcers prevented is similar with stool
antigen testing and retesting, breath test and retesting or any
strategy involving gastroscopy and retesting. This indicates that
the additional cost of more expensive screening strategies does not
confer any significant additional benefit and reflects the similar
sensitivity and specificity of these testing modalities.
Previous international modelling has shown that universal
screening of 20 year olds for H. pylori is a cost effective way of
reducing gastric cancer in a Chinese population [20]. Screening in
lower prevalence populations has also been shown to be cost
effective although the cost is significantly higher per quality
adjusted life year (QALY) [5].
Our model may underestimate the benefits of screening and
treatment as we did not include prevention of dyspepsia through
H. pylori treatment and the associated reduced doctor visits for
dyspepsia management, and potential for reduced hospital
admissions [21]. The benefits of test and treat strategies may also
be an underestimate as the cost of gastric cancer treatment may be
considerably more than the cost estimates used in this analysis in
patients over the age of 65 years [3]. The use of physician
assistants or clinic nurses to order the initial testing would also lead
to cost savings, and the use of more effective first line therapies
could improve cost effectiveness. However, the frequency of
treatment side effects, which reportedly occur in 22% of treated
patients and 8% of placebo patients [22] needs to be considered
and these additional side effects may increase costs.
H. pylori has been part of our gastrointestinal flora for 60000
years [23] so a recommendation for eradication should be made
with caution. H. pylori prevalence rates have been falling in
developed countries at the same time as allergic disease, reflux and
obesity have been increasing [24]. Some randomised trial evidence
demonstrates a small increase in weight after H. pylori eradication
[25]. H. pylori eradication is also associated with a rise in
prevalence of Barrett’s Oesophagus [26], and increasing oesoph-
ageal cancer rates [27]. Concern that H. pylori eradication can
lead to increased risk of gastro-oesophageal reflux disease (GERD)
has not been confirmed in a large systematic review [28]. In any
event this concern about oesophageal pathology is of small
magnitude compared with the potential reduction in gastric cancer
rates.
Antibiotic resistance to H. pylori is increasing and efficacy of
standard treatment for H. pylori in many countries is now less than
80%, primarily due to clarithromycin resistance [29]. This is
concerning for the implementation of a screening program. Other
options that can be more effective include sequential therapy with
PPI and amoxicillin for 5 days followed by PPI, clarithromycin
and metronidazole for 5 days) [29], and longer courses (10–14
days) of quadruple therapy, including bismuth, tetracycline,
metronidazole and a PPI [30].
Screening or empiric treatment for refugees and immigrants for
infectious conditions is currently recommended for a number of
pathogens. Empiric treatment for helminthic infections is cost
effective and recommended in some settings [31]. Treatment costs
for latent tuberculosis (TB) are over US 28000 (17,956 pounds)
per episode of TB prevented [32]. TB in the United States now
has a mortality less than 5% [33], compared to gastric cancer’s 5
year mortality of 84% [5]. Screening and treatment for Hepatitis B
virus is common in many immigrant groups, and is cost effective
even at a population prevalence of less than 2% [34].
Stool sampling is currently routinely recommended for helminth
detection for refugee groups arriving in many developed countries
[35], and faecal antigen testing for H. pylori could be incorporated
with stool testing for other pathogens, an additional important cost
saving measure.
The current American College of Gastroenterology and also
European guidelines do not recommend a general screen and treat
strategy for H. pylori infection to reduce the risk of gastric cancer;
and do not specifically address the issue of high risk populations
[6,36]. Asia Pacific guidelines, representing countries with a higher
H. pylori prevalence, do recommend general screening for H.
pylori in high risk populations although the strategy is not clearly
defined [18].
Our data provide important evidence on which to base future
recommendations.
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